BioSpace News Archive

BioVie Inc. today announced the participation of its management team in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that on February 05, 2024, the compensation committee of BridgeBio’s board of directors granted thirty-five new employees restricted stock units for an aggregate of 123,838 shares of the Company’s common stock.

Genprex, Inc. today announced that its Chief Financial Officer, Ryan Confer will be providing an overview of the Company’s gene therapies for cancer and diabetes at the upcoming BIO CEO & Investor Conference.

Roughly 11 percent of people living in the United States have type 2 diabetes and nearly 40 percent of adults have prediabetes, according to the Centers for Disease Control and Prevention.

Lavior Pharma is on a mission to address health disparities affecting African Americans, who are 60% more likely to be diagnosed with diabetes and three times more likely to undergo amputation as a result.

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, which is being held virtually.